Literature DB >> 2535672

Pituitary multicatalytic proteinase complex. Specificity of components and aspects of proteolytic activity.

M Orlowski1, C Michaud.   

Abstract

The 700-kDa multicatalytic proteinase complex from bovine pituitaries separates in polyacrylamide gel electrophoresis under dissociating and reducing conditions into 11 components with molecular masses ranging from 21 to 32 kDa. No higher molecular mass components were detected. A rabbit polyclonal antibody raised against the complex recognizes five immunoreactive components. As reported previously, the complex exhibits three distinct proteolytic activities designated as chymotrypsin-like, trypsin-like, and peptidylglutamyl-peptide hydrolyzing activities. All three activities are rather rapidly inactivated by 3,4-dichloroisocoumarin, a general serine protease inhibitor, however, the pseudo-first-order rate constants of inactivation of the three components differ within a wide range, with the chymotrypsin-like activity being most sensitive to inhibition. The peptidylglutamyl-peptide hydrolyzing activity is greatly activated by low concentrations of sodium dodecyl sulfate and fatty acids and seems to constitute the main component responsible for degradation of protein substrates. In addition to cleaving bonds on the carboxyl side of glutamyl residues, this activity also cleaves, albeit at a slower rate, bonds on the carboxyl side of hydrophobic residues; however, the secondary specificity of this component is clearly different from the chymotrypsin-like activity. Heparin selectively activates the chymotrypsin-like activity. The complex cleaves rapidly both native and dephosphorylated beta-casein in a reaction greatly accelerated by low concentrations of sodium dodecyl sulfate. The nature of proteolytic products, and also the rate of formation of acid-soluble, ninhydrin-reactive products, is different for the phosphorylated and dephosphorylated form of beta-casein, indicating that the degree of phosphorylation influences the rate and pattern of proteolysis.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2535672     DOI: 10.1021/bi00450a006

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  26 in total

1.  Synthetic peptide-based activators of the proteasome.

Authors:  S Wilk; W E Chen
Journal:  Mol Biol Rep       Date:  1997-03       Impact factor: 2.316

2.  Properties of subunits of the multicatalytic proteinase complex revealed by the use of subunit-specific antibodies.

Authors:  A J Rivett; S T Sweeney
Journal:  Biochem J       Date:  1991-08-15       Impact factor: 3.857

Review 3.  Proteasomes: multicatalytic proteinase complexes.

Authors:  A J Rivett
Journal:  Biochem J       Date:  1993-04-01       Impact factor: 3.857

4.  Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1.

Authors:  A K Nussbaum; T P Dick; W Keilholz; M Schirle; S Stevanović; K Dietz; W Heinemeyer; M Groll; D H Wolf; R Huber; H G Rammensee; H Schild
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

5.  Biochemical characterization of the 20S proteasome from the methanoarchaeon Methanosarcina thermophila.

Authors:  J A Maupin-Furlow; H C Aldrich; J G Ferry
Journal:  J Bacteriol       Date:  1998-03       Impact factor: 3.490

6.  Effects of Ghrelin on the Proteolytic Pathways of Alzheimer's Disease Neuronal Cells.

Authors:  Valentina Cecarini; Laura Bonfili; Massimiliano Cuccioloni; Jeffrey N Keller; Annadora J Bruce-Keller; Anna Maria Eleuteri
Journal:  Mol Neurobiol       Date:  2015-06-02       Impact factor: 5.590

7.  Differential ASC requirements reveal a key role for neutrophils and a noncanonical IL-1β response to Pseudomonas aeruginosa.

Authors:  Yash R Patankar; Rodwell Mabaera; Brent Berwin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-08-21       Impact factor: 5.464

Review 8.  Harnessing proteasome dynamics and allostery in drug design.

Authors:  Maria Gaczynska; Pawel A Osmulski
Journal:  Antioxid Redox Signal       Date:  2014-02-21       Impact factor: 8.401

Review 9.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

10.  Potent inhibition of endopeptidase 24.16 and endopeptidase 24.15 by the phosphonamide peptide N-(phenylethylphosphonyl)-Gly-L-Pro-L-aminohexanoic acid.

Authors:  H Barelli; V Dive; A Yiotakis; J P Vincent; F Checler
Journal:  Biochem J       Date:  1992-10-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.